 Drug Industry
"Drug Industry" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.
| Descriptor ID |
D004345
|
| MeSH Number(s) |
J01.576.318
|
| Concept/Terms |
Drug Industry- Drug Industry
- Pharmaceutical Industry
- Industry, Pharmaceutic
- Industries, Pharmaceutic
- Pharmaceutic Industries
- Pharmaceutic Industry
- Industry, Drug
- Drug Industries
- Industries, Drug
- Industry, Pharmaceutical
- Industries, Pharmaceutical
- Pharmaceutical Industries
|
Below are MeSH descriptors whose meaning is more general than "Drug Industry".
Below are MeSH descriptors whose meaning is more specific than "Drug Industry".
This graph shows the total number of publications written about "Drug Industry" by people in this website by year, and whether "Drug Industry" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 1 | 0 | 1 | | 1996 | 0 | 1 | 1 | | 1998 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2003 | 0 | 1 | 1 | | 2004 | 3 | 3 | 6 | | 2006 | 2 | 0 | 2 | | 2008 | 1 | 1 | 2 | | 2009 | 2 | 2 | 4 | | 2010 | 1 | 1 | 2 | | 2011 | 2 | 1 | 3 | | 2012 | 1 | 0 | 1 | | 2013 | 1 | 0 | 1 | | 2014 | 3 | 3 | 6 | | 2017 | 0 | 1 | 1 | | 2018 | 1 | 1 | 2 | | 2020 | 2 | 0 | 2 | | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Industry" by people in Profiles.
-
Strohbehn GW, Kacew AJ, Goldstein DA, Feldman RC, Ratain MJ. Combination therapy patents: a new front in evergreening. Nat Biotechnol. 2021 12; 39(12):1504-1510.
-
Zhang JX. Decreasing utilization and increasing prices of brand-name oral contraceptive pills: Implications to societal costs and market competition. PLoS One. 2020; 15(6):e0234463.
-
Schenck L, Erdemir D, Saunders Gorka L, Merritt JM, Marziano I, Ho R, Lee M, Bullard J, Boukerche M, Ferguson S, Florence AJ, Khan SA, Sun CC. Recent Advances in Co-processed APIs and Proposals for Enabling Commercialization of These Transformative Technologies. Mol Pharm. 2020 07 06; 17(7):2232-2244.
-
Lyman GH, Zon R, Harvey RD, Schilsky RL. Rationale, Opportunities, and Reality of Biosimilar Medications. N Engl J Med. 2018 May 24; 378(21):2036-2044.
-
Modi PK, Wang Y, Kirk PS, Dupree JM, Singer EA, Chang SL. The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications. Urology. 2018 Jul; 117:50-56.
-
Maruf M, Agarwal PK, Sidana A. The Sunshine Act and oncology: Lessons learned from urology. Semin Oncol. 2017 08; 44(4):265-266.
-
Conti RM, Gee RE, Sharfstein JM. Pharmaceuticals and Public Health. JAMA. 2016 Nov 22; 316(20):2083-2084.
-
Schilsky RL. Reply to F.E. Vera-Badillo et al. J Clin Oncol. 2014 Oct 01; 32(28):3198.
-
Greenberg SB, Vender JS. POINT: should academic physicians lecture as members of industry speaker bureaus? Yes. Chest. 2014 Aug; 146(2):250-252.
-
Greenberg SB, Vender JS. Rebuttal from Drs Greenberg and Vender. Chest. 2014 Aug; 146(2):254-256.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|